Fresenius SE & Co KGaA (FRE.DE) Delnica Cena
Fresenius SE & Co KGaA Cena
Prihodki so rasli 4,0 % letno v zadnjih 19 letih na 22,87 Mrd. EUR. Dobiček na delnico je rasel 6,2 % letno v zadnjih 19 letih. čista marža družbe Fresenius SE & Co KGaA je zdaj 5,5 %, večinoma stabilna z 4,9 % pred nekaj leti. Fresenius SE & Co KGaA trenutno ponuja dividendno donosnost okoli 2,17 %. Izplačilni delež je okoli 45 % dobička. Dividenda je rasla 10,0 % letno v zadnjih 19 letih. Mediana ciljne cene analitikov je 57,12 EUR, torej nad trenutno ceno za 23,9 %. Od 23 analitikov jih 21 priporoča nakup — skupni konsenz je Nakup.
Cena delnice Fresenius SE & Co KGaA
Do teh podatkov prek Eulerpool API
100.000 zahtevkov/mes. brezplačno · brez kartice
Fresenius SE & Co KGaA poslovni model in analiza delnice
Pogosto postavljena vprašanja o delnici Fresenius SE & Co KGaA
Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.
Fresenius SE is primarily active in the healthcare industry.
The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.
Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.
Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.
Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.
Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.
Analitiki trenutno določajo povprečno ciljno ceno 56,38 EUR za delnico Fresenius SE & Co KGaA (mediana: 57,12 EUR), kar pomeni +22,3 % glede na zadnjo ceno. Konsenz temelji na 23 ocenah.
23 analitikov trenutno ocenjuje delnico Fresenius SE & Co KGaA: 21 priporoča nakup, 2 držanje in 0 prodajo. Za 2026 analitiki pričakujejo, da bo Fresenius SE & Co KGaA ustvaril prihodke 23,72 Mrd. EUR in dobiček na delnico 3,67 EUR.
Delnica Fresenius SE & Co KGaA (FRE.DE) je uvrščena na 10 borzah, med njimi: London (0OO9.L), SIX (Zürich) (FREEUR.SW), XETRA (FRE.DE), Frankfurt (FRE.F), München (FRE.MU), Düsseldorf (FRE.DU), Hamburg (FRE.HM), Wien (FRE.VI).
Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.
pričakovane prihodki za Fresenius SE & Co KGaA znašajo 23,72 Mrd. EUR. Ta vrednost temelji na trenutnih finančnih podatkih in odraža poslovno uspešnost podjetja.
pričakovane dobiček za Fresenius SE & Co KGaA znaša 2,07 Mrd. EUR. Čisti dobiček odraža donosnost podjetja po odbitku vseh stroškov.
Razmerje cena-dobiček (P/E) Fresenius SE & Co KGaA je trenutno 12,57. Razmerje P/E primerja trenutno ceno delnice z dobičkom na delnico in pomoči vlagateljem oceniti vrednost delnice Fresenius SE & Co KGaA.
Razmerje cena-prihodki (P/S) Fresenius SE & Co KGaA je trenutno 1,09. Razmerje P/S primerja tržno vrednost s celotnimi letnimi prihodki in služi kot kazalnik vrednotenja delnice Fresenius SE & Co KGaA.
Eulerpool ocena kvalitete za Fresenius SE & Co KGaA je 3/10.
ISIN Fresenius SE & Co KGaA je DE0005785604. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.
WKN Fresenius SE & Co KGaA je 578560. WKN (Wertpapierkennnummer) je šestmestna nemška oznaka za identifikacijo vrednostnih papirjev.
Ticker Fresenius SE & Co KGaA je FRE.DE. Ticker simbol se uporablja za trgovanje z delnicami Fresenius SE & Co KGaA na borzi.
Fresenius SE & Co KGaA delnica
Fresenius SE & Co KGaA Konkurenčna skupina
Fresenius SE & Co KGaA Ticker
Fresenius SE & Co KGaA FIGI
Vse ključne kazalnike in poglobljeno analizo Fresenius SE & Co KGaA v detaljnem pregledu
Naša analiza delnic Fresenius SE & Co KGaA vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (P/E), razmerje cena/prihodki (P/S), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Fresenius SE & Co KGaA. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: